At the time of writing, Lineage Cell Therapeutics Inc [LCTX] stock is trading at $0.66, down -3.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LCTX shares have gain 9.96% over the last week, with a monthly amount glided 33.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lineage Cell Therapeutics Inc [AMEX: LCTX] stock has seen the most recent analyst activity on August 20, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $4. Previously, Robert W. Baird started tracking the stock with Outperform rating on November 02, 2022, and set its price target to $5. On June 14, 2022, B. Riley Securities initiated with a Buy rating and assigned a price target of $4 on the stock. Noble Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $8 on August 19, 2021. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $6 as its price target on March 31, 2021.
For the past year, the stock price of Lineage Cell Therapeutics Inc fluctuated between $0.37 and $1.15. Lineage Cell Therapeutics Inc [AMEX: LCTX] shares were valued at $0.66 at the most recent close of the market.
Analyzing the LCTX fundamentals
According to Lineage Cell Therapeutics Inc [AMEX:LCTX], the company’s sales were 9.56M for trailing twelve months, which represents an 4.02% jump. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -2.23%, Pretax Profit Margin comes in at -1.69%, and Net Profit Margin reading is -1.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.22 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6431 points at the first support level, and at 0.6216 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6831, and for the 2nd resistance point, it is at 0.7016.
Ratios To Look Out For
It is important to note that Lineage Cell Therapeutics Inc [AMEX:LCTX] has a current ratio of 3.82. As well, the Quick Ratio is 3.82, while the Cash Ratio is 3.66. Considering the valuation of this stock, the price to sales ratio is 15.88, the price to book ratio is 1.92.
Transactions by insiders
Recent insider trading involved BROADWOOD PARTNERS, L.P., Director, that happened on Jan 27 ’25 when 7.89 million shares were purchased. Chief Financial Officer, Howe Jill Ann completed a deal on Nov 26 ’24 to buy 15000.0 shares. Meanwhile, General Counsel Samuel George A. III bought 15000.0 shares on Nov 26 ’24.
